Compare SRRK & PSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | PSN |
|---|---|---|
| Founded | 2012 | 1944 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.3B |
| IPO Year | 2018 | 2019 |
| Metric | SRRK | PSN |
|---|---|---|
| Price | $56.23 | $48.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $56.17 | ★ $79.18 |
| AVG Volume (30 Days) | 981.1K | ★ 2.0M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.77 |
| EPS | N/A | ★ 0.49 |
| Revenue | N/A | ★ $6,364,245,000.00 |
| Revenue This Year | N/A | $5.87 |
| Revenue Next Year | $534.24 | $7.61 |
| P/E Ratio | ★ N/A | $94.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.07 | $36.26 |
| 52 Week High | $58.49 | $89.50 |
| Indicator | SRRK | PSN |
|---|---|---|
| Relative Strength Index (RSI) | 62.50 | 48.34 |
| Support Level | $45.81 | $48.16 |
| Resistance Level | $58.49 | $49.32 |
| Average True Range (ATR) | 2.38 | 1.71 |
| MACD | 0.63 | 0.20 |
| Stochastic Oscillator | 93.21 | 85.25 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.